{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-10T21:56:47.681853+00:00","company":{"ticker":"ABEO","cik":318306,"company_name":"ABEONA THERAPEUTICS INC."},"pagination":{"limit":100,"returned":41,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Avenue Venture Opportunities Fund, L.P.","detail":"credit_facility","count":2,"first_seen":"2024-01-08T23:59:59+00:00","last_seen":"2024-01-08T23:59:59+00:00","evidence_fact_ids":[82660,82661]},{"display_name":"Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P.","detail":"credit_facility","count":1,"first_seen":"2024-01-08T23:59:59+00:00","last_seen":"2024-01-08T23:59:59+00:00","evidence_fact_ids":[82662]},{"display_name":"Stifel, Nicolaus & Company, Incorporated","detail":"underwriting","count":1,"first_seen":"2024-05-03T23:59:59+00:00","last_seen":"2024-05-03T23:59:59+00:00","evidence_fact_ids":[55938]},{"display_name":"a group of investors","detail":"equity_purchase","count":1,"first_seen":"2022-11-03T23:59:59+00:00","last_seen":"2022-11-03T23:59:59+00:00","evidence_fact_ids":[200182]}],"lender":[{"display_name":"Avenue Venture Opportunities Fund, L.P.","detail":"senior_notes","count":1,"first_seen":"2025-07-18T23:59:59+00:00","last_seen":"2025-07-18T23:59:59+00:00","evidence_fact_ids":[43797]},{"display_name":"Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P.","detail":"term_loan","count":1,"first_seen":"2024-01-08T23:59:59+00:00","last_seen":"2024-01-08T23:59:59+00:00","evidence_fact_ids":[82666]}]},"facts":[{"fact_type":"shareholder_vote","fact_key":"22e242030d04acb3ad85c81b7d94a00dc79f6b79","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2026-06-12T20:30:25+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-12","outcome":"failed","proposal_text":"Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to remove the advance notice provision for director nominations","proposal_type":"charter_amendment","results":[{"broker_non_votes":"12,256,230","subject":null,"votes_abstain":"502,415","votes_against":"4,667,640","votes_for":"24,559,006","votes_withheld":null}]},"claim":"ABEONA THERAPEUTICS INC. shareholders rejected Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to remove the advance notice provision for director nominations at the 2026-06-12 meeting.","evidence_excerpt":"Proposal 5. Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to remove the advance notice provision for director nominations. A proposal to approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to remove the advance notice provision for director nominations was not approved because it did not receive the required affirmative vote of the holders of at least 66 2/3% of the outstanding shares of Common Stock. The proposal received the following votes: Votes For Votes Against Abstentions Broker Non-Votes 24,559,006 4,667,640 502,415 12,256,230","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-028458","anchor_url":"https://secwatch.observer/filing/0001493152-26-028458#claim-22e242030d04acb3ad85c81b7d94a00dc79f6b79","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315226028458/0001493152-26-028458-index.htm"},{"fact_type":"shareholder_vote","fact_key":"90703805cf5fbcc71fb959d9d63592718ae45798","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2026-06-12T20:30:25+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-12","outcome":"passed","proposal_text":"Approval of an Increase in the Number of Shares Reserved for Issuance Under the Second A&R Plan","proposal_type":"equity_plan","results":[{"broker_non_votes":"12,256,230","subject":null,"votes_abstain":"33,357","votes_against":"5,720,643","votes_for":"23,975,061","votes_withheld":null}]},"claim":"ABEONA THERAPEUTICS INC. shareholders approved Approval of an Increase in the Number of Shares Reserved for Issuance Under the Second A&R Plan at the 2026-06-12 meeting.","evidence_excerpt":"Proposal 4. Approval of an Increase in the Number of Shares Reserved for Issuance Under the Second A&R Plan. A proposal to an increase in the number of shares reserved for issuance under the Second Amended and Restated Abeona Therapeutics Inc. 2023 Equity Incentive Plan from 8,400,000 to 11,500,000 was approved by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 23,975,061 5,720,643 33,357 12,256,230","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-028458","anchor_url":"https://secwatch.observer/filing/0001493152-26-028458#claim-90703805cf5fbcc71fb959d9d63592718ae45798","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315226028458/0001493152-26-028458-index.htm"},{"fact_type":"shareholder_vote","fact_key":"868597754f6a97136fa2fd94124bb2f5b0924b04","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2026-06-12T20:30:25+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-12","outcome":"passed","proposal_text":"Ratification of the Appointment of Deloitte & Touche LLP as our Independent Registered Public Accounting Firm","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"—","subject":null,"votes_abstain":"42,810","votes_against":"1,381,486","votes_for":"40,560,995","votes_withheld":null}]},"claim":"ABEONA THERAPEUTICS INC. shareholders approved Ratification of the Appointment of Deloitte & Touche LLP as our Independent Registered Public Accounting Firm at the 2026-06-12 meeting.","evidence_excerpt":"Proposal 3. Ratification of the Appointment of Deloitte & Touche LLP as our Independent Registered Public Accounting Firm. A proposal to ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026 was approved by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 40,560,995 1,381,486 42,810 —","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-028458","anchor_url":"https://secwatch.observer/filing/0001493152-26-028458#claim-868597754f6a97136fa2fd94124bb2f5b0924b04","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315226028458/0001493152-26-028458-index.htm"},{"fact_type":"shareholder_vote","fact_key":"d431f719e85d3eb1367703e85da1aad95283c7e5","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2026-06-12T20:30:25+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-12","outcome":"passed","proposal_text":"Advisory Vote on Compensation of Named Executive Officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"12,256,230","subject":null,"votes_abstain":"1,916,542","votes_against":"4,511,866","votes_for":"23,300,653","votes_withheld":null}]},"claim":"ABEONA THERAPEUTICS INC. shareholders approved Advisory Vote on Compensation of Named Executive Officers at the 2026-06-12 meeting.","evidence_excerpt":"Proposal 2. Advisory Vote on Compensation of Named Executive Officers. An advisory vote to approve the compensation of the Company’s named executive officers was approved by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 23,300,653 4,511,866 1,916,542 12,256,230","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-028458","anchor_url":"https://secwatch.observer/filing/0001493152-26-028458#claim-d431f719e85d3eb1367703e85da1aad95283c7e5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315226028458/0001493152-26-028458-index.htm"},{"fact_type":"shareholder_vote","fact_key":"3c74d36de828384ba23bfd3cc5d169d7afe1163a","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2026-06-12T20:30:25+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-06-12","outcome":"passed","proposal_text":"Election of Directors","proposal_type":"director_election","results":[{"broker_non_votes":"12,256,230","subject":"Keith A. Goldan","votes_abstain":"70,514","votes_against":"1,352,589","votes_for":"28,305,958","votes_withheld":null},{"broker_non_votes":"12,256,230","subject":"Bernhardt G. Zeiher, M.D.","votes_abstain":"19,627","votes_against":"1,577,444","votes_for":"28,131,990","votes_withheld":null}]},"claim":"ABEONA THERAPEUTICS INC. shareholders approved Election of Directors at the 2026-06-12 meeting.","evidence_excerpt":"Proposal 1. Election of Directors. Keith A. Goldan and Bernhardt G. Zeiher, M.D. were elected to serve as Class 1 directors of the Company until the 2029 annual meeting of stockholders and until their successors are elected and qualified. The results of the election of directors are as follows: Nominee Votes For Votes Against Abstentions Broker Non-Votes Keith A. Goldan 28,305,958 1,352,589 70,514 12,256,230 Bernhardt G. Zeiher, M.D. 28,131,990 1,577,444 19,627 12,256,230","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-028458","anchor_url":"https://secwatch.observer/filing/0001493152-26-028458#claim-3c74d36de828384ba23bfd3cc5d169d7afe1163a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315226028458/0001493152-26-028458-index.htm"},{"fact_type":"executive_change","fact_key":"9fda15b76d","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2026-06-12T11:30:20+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2026-06-11","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Michael Amoroso resigned as Director at ABEONA THERAPEUTICS INC..","evidence_excerpt":"On June 11, 2026, Michael Amoroso resigned as a member of the Board of Directors (the “Board”) of Abeona Therapeutics Inc. (the “Company”) effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-26-028369","anchor_url":"https://secwatch.observer/filing/0001493152-26-028369#claim-9fda15b76d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315226028369/0001493152-26-028369-index.htm"},{"fact_type":"earnings_release","fact_key":"eddddd417a3f263e97fbe7bda7fa1a313fa9616f","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2026-05-13T11:30:50+00:00","payload":{"eps_text":"$(0.30) per basic and diluted common share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$(17.1) million","period_text":"first quarter ended March 31, 2026","report_date":"2026-05-13","result_type":"reported_results","revenue_text":"$8.7 million"},"claim":"ABEONA THERAPEUTICS INC. reported first quarter ended March 31, 2026 results: revenue $8.7 million, net income $(17.1) million, EPS $(0.30) per basic and diluted common share.","evidence_excerpt":"Abeona reported net product revenue of $8.7 million in the first quarter ending March 31, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-022610","anchor_url":"https://secwatch.observer/filing/0001493152-26-022610#claim-eddddd417a3f263e97fbe7bda7fa1a313fa9616f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315226022610/0001493152-26-022610-index.htm"},{"fact_type":"governance_change","fact_key":"a85ecbddb2d00248663535687cde545a16e0ed61","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2026-03-20T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":"2026-03-16","item_codes_triggered":["5.03"],"summary_text":"Adoption of Third Amended and Restated Bylaws effective March 16, 2026, making multiple changes including quorum increase to 50%, virtual meeting authorization, and enhanced stockholder proposal and director nomination procedures."},"claim":"ABEONA THERAPEUTICS INC.: Adoption of Third Amended and Restated Bylaws effective March 16, 2026, making multiple changes including quorum increase to 50%, virtual meeting authorization, and enhanced stockholder proposal and director nomination procedures (effective 2026-03-16).","evidence_excerpt":"On March 16, 2026, the Board of Directors (the “Board”) of Abeona Therapeutics Inc. (the “Company”) approved the adoption of the Third Amended and Restated Bylaws of the Company, effective as of March 16, 2026 (the “New Bylaws”), which amend and restate the Second Amended and Restated Bylaws of the Company, dated as of July 9, 2024 (the “Existing Bylaws”), in their entirety.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-011863","anchor_url":"https://secwatch.observer/filing/0001493152-26-011863#claim-a85ecbddb2d00248663535687cde545a16e0ed61","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315226011863/0001493152-26-011863-index.htm"},{"fact_type":"earnings_release","fact_key":"246145707965bcf943f8e72ec41e7f1ad13a270a","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2026-03-17T23:59:59+00:00","payload":{"eps_text":"$1.34 per basic and $1.01 per diluted common share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$71.2 million","period_text":"year ended December 31, 2025","report_date":"2026-03-17","result_type":"reported_results","revenue_text":"$5.8 million"},"claim":"ABEONA THERAPEUTICS INC. reported year ended December 31, 2025 results: revenue $5.8 million, net income $71.2 million, EPS $1.34 per basic and $1.01 per diluted common share.","evidence_excerpt":"Abeona reported total revenue of $5.8 million for the year ended December 31, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-26-010408","anchor_url":"https://secwatch.observer/filing/0001493152-26-010408#claim-246145707965bcf943f8e72ec41e7f1ad13a270a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315226010408/0001493152-26-010408-index.htm"},{"fact_type":"debt_financing","fact_key":"0b366cc5a20a9848a0a9caf10293e40506063873","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2025-07-18T23:59:59+00:00","payload":{"counterparty":"Avenue Venture Opportunities Fund, L.P.","effective_date":"2025-07-18","event":"amendment","instrument_type":"senior_notes","interest_rate_text":"13.5% to a fixed rate of 11.75% per annum","item_codes_triggered":["2.03"],"maturity_text":null,"principal_text":null},"claim":"ABEONA THERAPEUTICS INC. amended senior notes with Avenue Venture Opportunities Fund, L.P. at 13.5% to a fixed rate of 11.75% per annum.","evidence_excerpt":"The Amendment reduces the interest rate for senior secured term loan owed under the Loan Agreement from 13.5% to a fixed rate of 11.75% per annum.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001641172-25-020227","anchor_url":"https://secwatch.observer/filing/0001641172-25-020227#claim-0b366cc5a20a9848a0a9caf10293e40506063873","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000164117225020227/0001641172-25-020227-index.htm"},{"fact_type":"ma_transaction","fact_key":"796f457274412ff4454dbca6ca43b57065214826","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2025-07-02T23:59:59+00:00","payload":{"action":"disposition","closing_date":"2025-06-27","consideration_text":"gross proceeds of $155 million","counterparty":"buyer","effective_date":"2025-06-27","item_codes_triggered":["2.01"]},"claim":"ABEONA THERAPEUTICS INC. completed a disposition involving buyer for gross proceeds of $155 million (closed 2025-06-27).","evidence_excerpt":"terms of an asset purchase agreement dated May 9, 2025 (the “PRV Asset Purchase Agreement”).\nPursuant to the PRV Asset Purchase Agreement, the Company received gross proceeds of $155 million from the buyer upon the closing of\nthe Asset Sale. The\nforegoing description of the PRV Asset Purchase Agreement does not purport to be complete and is qualified in its entirety","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001641172-25-017460","anchor_url":"https://secwatch.observer/filing/0001641172-25-017460#claim-796f457274412ff4454dbca6ca43b57065214826","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000164117225017460/0001641172-25-017460-index.htm"},{"fact_type":"executive_change","fact_key":"240c3b17dd","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2024-08-14T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-08-12","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Eric Crombez was appointed as Director at ABEONA THERAPEUTICS INC..","evidence_excerpt":"appointed Bernhardt G. Zeiher, MD, FCCP, FACP, on August 8, 2024 and Eric Crombez, MD on August 12, 2024 as members of the Board of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-031862","anchor_url":"https://secwatch.observer/filing/0001493152-24-031862#claim-240c3b17dd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315224031862/0001493152-24-031862-index.htm"},{"fact_type":"executive_change","fact_key":"ff4977ec32","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2024-08-14T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-08-08","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Bernhardt G. Zeiher was appointed as Director at ABEONA THERAPEUTICS INC..","evidence_excerpt":"appointed Bernhardt G. Zeiher, MD, FCCP, FACP, on August 8, 2024 and Eric Crombez, MD on August 12, 2024 as members of the Board of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-031862","anchor_url":"https://secwatch.observer/filing/0001493152-24-031862#claim-ff4977ec32","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315224031862/0001493152-24-031862-index.htm"},{"fact_type":"earnings_release","fact_key":"901cc2d51002f3c9ee6178b4c5d7ad3b8fd4f450","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2024-05-15T23:59:59+00:00","payload":{"eps_text":"$1.16 loss per common share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss was $31.6 million for the first quarter of 2024, or $1.16 loss per common share","period_text":"first quarter of 2024","report_date":"2024-05-15","result_type":"reported_results","revenue_text":null},"claim":"ABEONA THERAPEUTICS INC. reported first quarter of 2024 results: net income Net loss was $31.6 million for the first quarter of 2024, or $1.16 loss per common share, EPS $1.16 loss per common share.","evidence_excerpt":"Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the first quarter of 2024","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-019449","anchor_url":"https://secwatch.observer/filing/0001493152-24-019449#claim-901cc2d51002f3c9ee6178b4c5d7ad3b8fd4f450","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315224019449/0001493152-24-019449-index.htm"},{"fact_type":"material_agreement","fact_key":"f6c5a0748ec25c2ffaeeb257bb674318926192d9","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2024-05-03T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"Stifel, Nicolaus & Company, Incorporated","effective_date":"2024-05-03","item_codes_triggered":["1.01"],"value_text":"$70.2 million"},"claim":"ABEONA THERAPEUTICS INC. entered into Underwriting Agreement with Stifel, Nicolaus & Company, Incorporated valued at $70.2 million (effective 2024-05-03).","evidence_excerpt":"On May 3, 2024, Abeona Therapeutics Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Stifel, Nicolaus & Company, Incorporated (the “Underwriter”) relating to the issuance and sale of an aggregate of (a) 12,285,056 shares of the Company’s common stock (the “Shares”), and (b) pre-funded warrants to purchase 6,142,656 shares of the Company’s common stock (the “Pre-Funded Warrants”) in an underwritten offering (the “Offering”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-017768","anchor_url":"https://secwatch.observer/filing/0001493152-24-017768#claim-f6c5a0748ec25c2ffaeeb257bb674318926192d9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315224017768/0001493152-24-017768-index.htm"},{"fact_type":"earnings_release","fact_key":"5ac1d067d6f4b9da3b054c7d7bc5786c6c01a3bd","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2024-05-03T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended March 31, 2024","report_date":"2024-03-31","result_type":"preliminary_results","revenue_text":null},"claim":"ABEONA THERAPEUTICS INC. reported preliminary financial results for the quarter ended March 31, 2024.","evidence_excerpt":"the Company’s cash, cash equivalents, restricted cash and short-term investments were approximately $62.7 million. This financial information is preliminary and subject to change in connection with the completion of the Company’s financial statements for the quarter ended March 31, 2024.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-017625","anchor_url":"https://secwatch.observer/filing/0001493152-24-017625#claim-5ac1d067d6f4b9da3b054c7d7bc5786c6c01a3bd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315224017625/0001493152-24-017625-index.htm"},{"fact_type":"shareholder_vote","fact_key":"55499a1b2bf8ad3d5cff231ba0250af3c4a622cd","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2024-04-24T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-04-24","outcome":"passed","proposal_text":"Ratification of the Appointment of Deloitte & Touche LLP as our Independent Registered Public Accounting Firm","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"193,650","votes_against":"136,942","votes_for":"14,720,159","votes_withheld":null}]},"claim":"ABEONA THERAPEUTICS INC. shareholders approved Ratification of the Appointment of Deloitte & Touche LLP as our Independent Registered Public Accounting Firm at the 2024-04-24 meeting.","evidence_excerpt":"A proposal to ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024 was approved by the following votes: Votes Non-Votes 14,720,159 136,942 193,650 —","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-015792","anchor_url":"https://secwatch.observer/filing/0001493152-24-015792#claim-55499a1b2bf8ad3d5cff231ba0250af3c4a622cd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315224015792/0001493152-24-015792-index.htm"},{"fact_type":"shareholder_vote","fact_key":"e9b8a3c0643c7012a440b4c6b9d9e56572c07130","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2024-04-24T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-04-24","outcome":"passed","proposal_text":"Advisory Vote on Compensation of Named Executive Officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"5,093,839","subject":null,"votes_abstain":"24,341","votes_against":"402,844","votes_for":"9,529,727","votes_withheld":null}]},"claim":"ABEONA THERAPEUTICS INC. shareholders approved Advisory Vote on Compensation of Named Executive Officers at the 2024-04-24 meeting.","evidence_excerpt":"An advisory vote to approve the compensation of the Company’s named executive officers was approved by the following votes: Votes Non-Votes 9,529,727 402,844 24,341 5,093,839","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-015792","anchor_url":"https://secwatch.observer/filing/0001493152-24-015792#claim-e9b8a3c0643c7012a440b4c6b9d9e56572c07130","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315224015792/0001493152-24-015792-index.htm"},{"fact_type":"shareholder_vote","fact_key":"5eecae1659b6b8e8780bfa8ae1dd4d725a3b4ac9","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2024-04-24T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-04-24","outcome":"passed","proposal_text":"Approval of an Increase in the Number of Shares Reserved for Issuance Under the A&R Plan","proposal_type":"equity_plan","results":[{"broker_non_votes":"5,093,839","subject":null,"votes_abstain":"27,686","votes_against":"570,314","votes_for":"9,358,912","votes_withheld":null}]},"claim":"ABEONA THERAPEUTICS INC. shareholders approved Approval of an Increase in the Number of Shares Reserved for Issuance Under the A&R Plan at the 2024-04-24 meeting.","evidence_excerpt":"A proposal to approve an increase in the number of shares reserved for issuance under the A&R Plan from 1,700,000 to 3,200,000 shares was approved based on the following votes: Votes Non-Votes 9,358,912 570,314 27,686 5,093,839","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-015792","anchor_url":"https://secwatch.observer/filing/0001493152-24-015792#claim-5eecae1659b6b8e8780bfa8ae1dd4d725a3b4ac9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315224015792/0001493152-24-015792-index.htm"},{"fact_type":"shareholder_vote","fact_key":"427c22e83195be5c655bafff12bee52519416545","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2024-04-24T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-04-24","outcome":"passed","proposal_text":"Election of Directors","proposal_type":"director_election","results":[{"broker_non_votes":"5,093,839","subject":"Leila Alland","votes_abstain":"12,938","votes_against":null,"votes_for":"8,985,852","votes_withheld":"958,122"},{"broker_non_votes":"5,093,839","subject":"Vishwas Seshadri","votes_abstain":"13,312","votes_against":null,"votes_for":"9,922,210","votes_withheld":"21,390"}]},"claim":"ABEONA THERAPEUTICS INC. shareholders approved Election of Directors at the 2024-04-24 meeting.","evidence_excerpt":"Leila Alland and Vishwas Seshadri were elected to serve as Class 2 directors of the Company until the 2027 annual meeting of stockholders and until their successors are elected and qualified. The results of the election of directors are as follows: Nominee Votes Non-Votes Leila Alland 8,985,852 958,122 12,938 5,093,839 Vishwas Seshadri 9,922,210 21,390 13,312 5,093,839","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-015792","anchor_url":"https://secwatch.observer/filing/0001493152-24-015792#claim-427c22e83195be5c655bafff12bee52519416545","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315224015792/0001493152-24-015792-index.htm"},{"fact_type":"earnings_release","fact_key":"03f32659d4947b22aefa8ce79b263cd559e9c0cd","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2024-03-18T23:59:59+00:00","payload":{"eps_text":"-2.53","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"-54.2 million","period_text":"full year ended December 31, 2023","report_date":"2024-03-18","result_type":"reported_results","revenue_text":"3.5 million"},"claim":"ABEONA THERAPEUTICS INC. reported full year ended December 31, 2023 results: revenue 3.5 million, net income -54.2 million, EPS -2.53.","evidence_excerpt":"sales of pz-cel, if approved, or proceeds from the sale of a Priority Review Voucher, if awarded by the\nFDA. License\nand other revenues for the year ended December 31, 2023 were $3.5 million, as compared to $1.4 million for the same period of 2022. The\nrevenues in both years primarily represent clinical milestone payments under a licensing agreement with Taysha Gene","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001493152-24-010206","anchor_url":"https://secwatch.observer/filing/0001493152-24-010206#claim-03f32659d4947b22aefa8ce79b263cd559e9c0cd","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315224010206/0001493152-24-010206-index.htm"},{"fact_type":"debt_financing","fact_key":"229bef614f6b836952ab502da2aaddac52f28fc8","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2024-01-08T23:59:59+00:00","payload":{"counterparty":"Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P.","effective_date":"2024-01-08","event":"incurrence","instrument_type":"term_loan","interest_rate_text":"greater of (i) the prime rate, as published by the Wall Street Journal from time","item_codes_triggered":["2.03"],"maturity_text":"July 1, 2027","principal_text":"$20 million"},"claim":"ABEONA THERAPEUTICS INC. incurred term loan of $20 million with Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P. at greater of (i) the prime rate, as published by the Wall Street Journal from time maturing July 1, 2027.","evidence_excerpt":"and the Lenders. The Loan\nAgreement provides for senior secured term loans (the “ Loans ”) in an aggregate principal amount up to $50 million,\nwith (i) a committed tranche of $20 million advanced on the Closing Date (“ Tranche 1 ”), (ii) a committed tranche of\nup to $10 million which may be advanced upon the request of the Company between June 30, 2024 and","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-24-001660","anchor_url":"https://secwatch.observer/filing/0001493152-24-001660#claim-229bef614f6b836952ab502da2aaddac52f28fc8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315224001660/0001493152-24-001660-index.htm"},{"fact_type":"material_agreement","fact_key":"af647a5f8689f03ad7e49695bd5eae0c763fabe3","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2024-01-08T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Warrants","agreement_type":"credit_facility","counterparty":"Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P.","effective_date":"2024-01-08","item_codes_triggered":["1.01"],"value_text":"Warrants to purchase up to $480,000 and $1,920,000 worth of shares respectively"},"claim":"ABEONA THERAPEUTICS INC. entered into Warrants with Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P. valued at Warrants to purchase up to $480,000 and $1,920,000 worth of shares respectively (effective 2024-01-08).","evidence_excerpt":"On the Closing Date and pursuant to the funding of Tranche 1 of the Loan Agreement, the Company issued to each of Avenue and Avenue 2 (collectively, the “ Warrantholders ”) warrants to purchase up to $480,000 and $1,920,000 worth of shares, respectively, of Company common stock (each, a “ Warrant ” and collectively, the “ Warrants ”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-001660","anchor_url":"https://secwatch.observer/filing/0001493152-24-001660#claim-af647a5f8689f03ad7e49695bd5eae0c763fabe3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315224001660/0001493152-24-001660-index.htm"},{"fact_type":"material_agreement","fact_key":"3ed614b22ebeb5dfca2fb5bc5c3ca6152f7f6cb2","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2024-01-08T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Supplement to Loan and Security Agreement","agreement_type":"credit_facility","counterparty":"Avenue Venture Opportunities Fund, L.P.","effective_date":"2024-01-08","item_codes_triggered":["1.01"],"value_text":"Conversion Right to convert up to $3 million of principal into common stock; Participation Right to"},"claim":"ABEONA THERAPEUTICS INC. entered into Supplement to Loan and Security Agreement with Avenue Venture Opportunities Fund, L.P. valued at Conversion Right to convert up to $3 million of principal into common stock; Participation Right to (effective 2024-01-08).","evidence_excerpt":"Also on January 8, 2024, the Companies entered into a Supplement to the Agreement (collectively with the Agreement, the “ Loan Agreement ”) with the Agent and the Lenders.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-24-001660","anchor_url":"https://secwatch.observer/filing/0001493152-24-001660#claim-3ed614b22ebeb5dfca2fb5bc5c3ca6152f7f6cb2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315224001660/0001493152-24-001660-index.htm"},{"fact_type":"material_agreement","fact_key":"7c5f3daa364e0469f0885b1f82f768efb7566fb9","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2024-01-08T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Loan and Security Agreement","agreement_type":"credit_facility","counterparty":"Avenue Venture Opportunities Fund, L.P.","effective_date":"2024-01-08","item_codes_triggered":["1.01"],"value_text":"$50,000,000"},"claim":"ABEONA THERAPEUTICS INC. entered into Loan and Security Agreement with Avenue Venture Opportunities Fund, L.P. valued at $50,000,000 (effective 2024-01-08).","evidence_excerpt":"On January 8, 2024 (the “ Closing Date ”), Abeona Therapeutics Inc., a Delaware corporation (“ Abeona ”) and its subsidiaries MacroChem Corporation, a Delaware corporation (“ MacroChem ”) and Abeona Therapeutics LLC, an Ohio corporation (“ Abeona OH ” and, together with Abeona and MacroChem, each individually, a “ Company ” and collectively, the “ Companies ”) entered into a Loan and Security Agreement (the “ Agreement ”) with Avenue Venture Opportunities Fund, L.P., a Delaware limited partnership, as administrative agent and collateral agent (“ Avenue ” and the “ Agent ”) and Avenue Venture Opportunities Fund II, L.P. , a Delaware limited partnership (“ Avenue 2 ” and, together with Avenue, the “ Lenders ”).","confidence":0.99,"filing_url":"https://secwatch.observer/filing/0001493152-24-001660","anchor_url":"https://secwatch.observer/filing/0001493152-24-001660#claim-7c5f3daa364e0469f0885b1f82f768efb7566fb9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315224001660/0001493152-24-001660-index.htm"},{"fact_type":"earnings_release","fact_key":"707bc294ee6cc194a47df982051668675d424f10","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2023-11-13T23:59:59+00:00","payload":{"eps_text":"$0.48 loss per common share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss attributable to common shareholders was $11.8 million for the third quarter of 2023, or $0.48 loss per common s","period_text":"the third quarter of 2023","report_date":"2023-11-13","result_type":"reported_results","revenue_text":null},"claim":"ABEONA THERAPEUTICS INC. reported the third quarter of 2023 results: net income Net loss attributable to common shareholders was $11.8 million for the third quarter of 2023, or $0.48 loss per common s, EPS $0.48 loss per common share.","evidence_excerpt":"Net loss attributable to common shareholders was $11.8 million for the third quarter of 2023, or $0.48 loss per common share as compared to a net loss attributable to common shareholders of $6.4 million, or $1.00 loss per common share, in the third quarter of 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-23-040318","anchor_url":"https://secwatch.observer/filing/0001493152-23-040318#claim-707bc294ee6cc194a47df982051668675d424f10","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315223040318/0001493152-23-040318-index.htm"},{"fact_type":"auditor_change","fact_key":"350a2c2d5c48aa232711fa1668a52ceda102cd55","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2023-10-18T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"Deloitte & Touche LLP","disagreement_text":null,"effective_date":"2023-10-17","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"ABEONA THERAPEUTICS INC. engaged Deloitte & Touche LLP as its auditor.","evidence_excerpt":"On October 17, 2023, the Audit Committee (the \"Committee\") of the Board of Directors of Abeona Therapeutics, Inc. (\"we,\" \"our,\" \"us,\" or the \"Company\") approved the engagement of Deloitte & Touche LLP (\"Deloitte\"), to serve as our independent registered public accounting firm for the fiscal year ending December 31, 2023 with such appointment to be effective as of October 17, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-037561","anchor_url":"https://secwatch.observer/filing/0001493152-23-037561#claim-350a2c2d5c48aa232711fa1668a52ceda102cd55","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315223037561/0001493152-23-037561-index.htm"},{"fact_type":"auditor_change","fact_key":"4f9ce64344955caa07c93b66d75e5bc7870bd945","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2023-10-18T23:59:59+00:00","payload":{"action":"dismissal","auditor_name":"Whitley Penn LLP","disagreement_text":null,"effective_date":"2023-10-16","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"ABEONA THERAPEUTICS INC. dismissed Whitley Penn LLP as its auditor.","evidence_excerpt":"On October 16, 2023, Whitley Penn LLP (\"Whitley Penn\") was informed that the Committee approved Whitley Penn’s dismissal as the Company’s independent registered public accounting firm with such dismissal to be effective immediately.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-037561","anchor_url":"https://secwatch.observer/filing/0001493152-23-037561#claim-4f9ce64344955caa07c93b66d75e5bc7870bd945","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315223037561/0001493152-23-037561-index.htm"},{"fact_type":"earnings_release","fact_key":"510c1649b2418f006f2bfa48759e98673808f9c7","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2023-08-08T23:59:59+00:00","payload":{"eps_text":"$0.92 loss per common share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$16.7 million","period_text":"second quarter of 2023","report_date":"2023-08-08","result_type":"reported_results","revenue_text":"$3.5 million"},"claim":"ABEONA THERAPEUTICS INC. reported second quarter of 2023 results: revenue $3.5 million, net income $16.7 million, EPS $0.92 loss per common share.","evidence_excerpt":"direct offering\nin July 2023, are sufficient resources to fund operations into the fourth quarter of 2024. License\nand other revenues in the second quarter of 2023 were $3.5 million, compared to $1.0 million in the second quarter of 2022. Research\nand development expenses for the three months ended June 30, 2023 were $8.5 million, compared to $6.7 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-027107","anchor_url":"https://secwatch.observer/filing/0001493152-23-027107#claim-510c1649b2418f006f2bfa48759e98673808f9c7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315223027107/0001493152-23-027107-index.htm"},{"fact_type":"material_agreement","fact_key":"71103c012591ba8002a8b21a85317fb2fdcd5d96","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2023-07-03T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase Agreement","agreement_type":"equity_purchase","counterparty":"certain existing institutional investors","effective_date":"2023-07-03","item_codes_triggered":["1.01"],"value_text":"approximately $22.9 million"},"claim":"ABEONA THERAPEUTICS INC. entered into Purchase Agreement with certain existing institutional investors valued at approximately $22.9 million (effective 2023-07-03).","evidence_excerpt":"On July 3, 2023, Abeona Therapeutics Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain existing institutional investors relating to the issuance and sale of an aggregate of (a) 3,284,407 shares of the Company’s common stock (the “Shares”), and (b) pre-funded warrants to purchase 2,919,140 shares of the Company’s common stock (the “Pre-Funded Warrants”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-023235","anchor_url":"https://secwatch.observer/filing/0001493152-23-023235#claim-71103c012591ba8002a8b21a85317fb2fdcd5d96","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315223023235/0001493152-23-023235-index.htm"},{"fact_type":"earnings_release","fact_key":"2d3eaa9fbdb4cb3d6d4fde7526c36bb3b5891308","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2023-05-11T23:59:59+00:00","payload":{"eps_text":"$0.54 loss per common share","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"Net loss was $9.1 million for the first quarter of 2023, or $0.54 loss per common share","period_text":"the first quarter of 2023","report_date":"2023-05-11","result_type":"reported_results","revenue_text":"nil"},"claim":"ABEONA THERAPEUTICS INC. reported the first quarter of 2023 results: revenue nil, net income Net loss was $9.1 million for the first quarter of 2023, or $0.54 loss per common share, EPS $0.54 loss per common share. Guidance reaffirmed.","evidence_excerpt":"Abeona Therapeutics Inc. issued a press release regarding its results of operations and financial condition for the first quarter of 2023.","confidence":0.92,"filing_url":"https://secwatch.observer/filing/0001493152-23-016277","anchor_url":"https://secwatch.observer/filing/0001493152-23-016277#claim-2d3eaa9fbdb4cb3d6d4fde7526c36bb3b5891308","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315223016277/0001493152-23-016277-index.htm"},{"fact_type":"earnings_release","fact_key":"fbd77a66548c6a1bb70754b3ef5218811ae51d6d","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2023-03-29T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$5.53 loss per common share","period_text":"full year 2022","report_date":"2023-03-29","result_type":"reported_results","revenue_text":"$1.4 million"},"claim":"ABEONA THERAPEUTICS INC. reported full year 2022 results: revenue $1.4 million, net income $5.53 loss per common share.","evidence_excerpt":"License and other revenues for the year ended December 31, 2022 were $1.4 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-23-009382","anchor_url":"https://secwatch.observer/filing/0001493152-23-009382#claim-fbd77a66548c6a1bb70754b3ef5218811ae51d6d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315223009382/0001493152-23-009382-index.htm"},{"fact_type":"earnings_release","fact_key":"d6e9181bb4e185a909b1544f6fcf5a8d11b86dcf","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2022-11-14T23:59:59+00:00","payload":{"eps_text":"$1.48 loss per common share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$9.5 million","period_text":"third quarter of 2022","report_date":"2022-11-14","result_type":"reported_results","revenue_text":null},"claim":"ABEONA THERAPEUTICS INC. reported third quarter of 2022 results: net income $9.5 million, EPS $1.48 loss per common share.","evidence_excerpt":"Net loss attributable to common shareholders for the third quarter of 2022 was $9.5 million, or $1.48 loss per common share as compared to $7.0 million, or $1.80 loss per common share, in the third quarter of 2021.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-22-031599","anchor_url":"https://secwatch.observer/filing/0001493152-22-031599#claim-d6e9181bb4e185a909b1544f6fcf5a8d11b86dcf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315222031599/0001493152-22-031599-index.htm"},{"fact_type":"material_agreement","fact_key":"c36cc18a2c791bdfaf8f9d6b76ef375ed21fe3b7","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2022-11-03T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"a group of investors (the “Purchasers”)","effective_date":"2022-11-03","item_codes_triggered":["1.01"],"value_text":"approximately $35.0 million"},"claim":"ABEONA THERAPEUTICS INC. entered into Securities Purchase Agreement with a group of investors (the “Purchasers”) valued at approximately $35.0 million (effective 2022-11-03).","evidence_excerpt":"Abeona Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a group of investors (the “Purchasers”) providing for the private placement (the “Private Placement”) to the Purchasers of (i) 7,065,946 shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”) (ii) pre-funded warrants to purchase 543,933 shares of Common Stock with a term of five years from the issuance date (the “Pre-Funded Warrants”) and (iii) warrants to purchase 7,609,879 shares of Common Stock with a term of five years from the issuance date (the “Common Warrants” and together with the Pre-Funded Warrants, the “Warrants”), for an aggregate purchase price of approximately $35.0 million.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-22-030374","anchor_url":"https://secwatch.observer/filing/0001493152-22-030374#claim-c36cc18a2c791bdfaf8f9d6b76ef375ed21fe3b7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315222030374/0001493152-22-030374-index.htm"},{"fact_type":"executive_change","fact_key":"fa1e517040","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2022-03-09T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-03-14","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Joseph Vazzano was appointed as Chief Financial Officer at ABEONA THERAPEUTICS INC..","evidence_excerpt":"Also on March 3, 2022, the Board appointed Joseph Vazzano as Chief Financial Officer effective March 14, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-22-006398","anchor_url":"https://secwatch.observer/filing/0001493152-22-006398#claim-fa1e517040","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315222006398/0001493152-22-006398-index.htm"},{"fact_type":"executive_change","fact_key":"d3a1bbe182","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2022-03-09T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-03-31","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":"Joseph Vazzano","successor_named":true},"claim":"Edward Carr resigned as Chief Financial Officer at ABEONA THERAPEUTICS INC..","evidence_excerpt":"On March 3, 2022, Edward Carr, Chief Financial Officer and Chief Accounting Officer of Abeona Therapeutics Inc. (the “Company”), notified the Company of his resignation effective March 31, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-22-006398","anchor_url":"https://secwatch.observer/filing/0001493152-22-006398#claim-d3a1bbe182","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315222006398/0001493152-22-006398-index.htm"},{"fact_type":"executive_change","fact_key":"2de40d7fa2","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2021-09-21T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2021-10-15","interim":false,"role":"President and Chief Executive Officer and director","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Vishwas Seshadri was appointed as President and Chief Executive Officer and director at ABEONA THERAPEUTICS INC..","evidence_excerpt":"the Board appointed Vishwas Seshadri, Ph.D., M.B.A., as President and Chief Executive Officer and director effective October 15, 2021.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-21-023269","anchor_url":"https://secwatch.observer/filing/0001493152-21-023269#claim-2de40d7fa2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315221023269/0001493152-21-023269-index.htm"},{"fact_type":"executive_change","fact_key":"cccf43dbdc","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2021-09-21T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2021-10-15","interim":false,"role":"Chairman of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Michael Amoroso was appointed as Chairman of the Board at ABEONA THERAPEUTICS INC..","evidence_excerpt":"the Board voted unanimously to appoint Mr. Amoroso Chairman of the Board effective October 15.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-21-023269","anchor_url":"https://secwatch.observer/filing/0001493152-21-023269#claim-cccf43dbdc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315221023269/0001493152-21-023269-index.htm"},{"fact_type":"executive_change","fact_key":"23b5ef9e2d","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2021-09-21T23:59:59+00:00","payload":{"action":"retired and resigned","action_category":"departure","departure_tone":"retirement","effective_date":"2021-10-14","interim":false,"role":"Chairman of the Board","role_category":"chair","successor_name":"Michael Amoroso","successor_named":true},"claim":"Steven Rouhandeh departed as Chairman of the Board at ABEONA THERAPEUTICS INC..","evidence_excerpt":"Steven Rouhandeh, Chairman of the Board, notified the Company of his retirement and resignation as a member of the Board effective October 14.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-21-023269","anchor_url":"https://secwatch.observer/filing/0001493152-21-023269#claim-23b5ef9e2d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315221023269/0001493152-21-023269-index.htm"},{"fact_type":"executive_change","fact_key":"7dfa531b7b","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2021-09-21T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2021-10-14","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":"Vishwas Seshadri","successor_named":true},"claim":"Michael Amoroso resigned as President and Chief Executive Officer at ABEONA THERAPEUTICS INC..","evidence_excerpt":"Michael Amoroso, President and Chief Executive Officer of Abeona Therapeutics Inc. (the “Company”), and a member of the Board of Directors (the “Board”), notified the Company of his resignation as President and Chief Executive Officer effective October 14, 2021.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-21-023269","anchor_url":"https://secwatch.observer/filing/0001493152-21-023269#claim-7dfa531b7b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315221023269/0001493152-21-023269-index.htm"},{"fact_type":"executive_change","fact_key":"b175c82503","cik":318306,"ticker":"ABEO","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2021-08-13T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2021-08-10","interim":false,"role":"Senior Vice President, Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Edward Carr was appointed as Senior Vice President, Chief Financial Officer at ABEONA THERAPEUTICS INC..","evidence_excerpt":"appointed Edward Carr, the Company’s Chief Accounting Officer, as Senior Vice President, Chief Financial Officer, effective on that same date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001493152-21-019797","anchor_url":"https://secwatch.observer/filing/0001493152-21-019797#claim-b175c82503","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/318306/000149315221019797/0001493152-21-019797-index.htm"}]}